Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KYNU | Q16719 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | CTSK | P43235 | 5/20 | 0.56 |
| ▸ | CTSS | P25774 | 4/20 | 0.55 |
| ▸ | CTSL | P07711 | 3/20 | 0.55 |
| ▸ | CTSB | P07858 | 3/20 | 0.55 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.54 |
| ▸ | TACR1 | P25103 | 2/20 | 0.53 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4346138 | 1.00 | KYNU (0.63) | KYNUALDH1A1ALOX15CTSKCTSS | |
| SCHEMBL3258258 | 1.00 | KYNU (0.63) | KYNUALDH1A1ALOX15CTSKCTSS | |
| Hydrochloric Acid SCHEMBL3258256 | 0.99 | KYNU (0.62) | KYNUALDH1A1ALOX15CTSKCTSS | |
| Hydrochloric Acid SCHEMBL3603216 | 0.99 | KYNU (0.62) | KYNUALDH1A1ALOX15CTSKCTSS | |
| Hydrochloric Acid SCHEMBL3603219 | 0.99 | KYNU (0.62) | KYNUALDH1A1ALOX15CTSKCTSS | |
| Trifluoroacetic Acid SCHEMBL5729191 | 0.93 | ALDH1A1 (0.58) | KYNUALDH1A1ALOX15CTSKCTSS | |
| SCHEMBL29521405 | 0.91 | CTSK (0.56) | KYNUALDH1A1ALOX15CTSKCTSS | |
| SCHEMBL29017554 | 0.91 | CTSK (0.56) | KYNUALDH1A1ALOX15CTSKCTSS | |
| SCHEMBL30437751 | 0.91 | CTSK (0.56) | KYNUALDH1A1ALOX15CTSKCTSS | |
| Hydrochloric Acid SCHEMBL6933213 | 0.90 | CTSK (0.54) | KYNUALDH1A1ALOX15CTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11530180-B2 | Alpha-5 beta-1 inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-12-20 | — | — | US | disclosed |
| EP-4072541-A1 | ALPHA-5 BETA-1 INHIBITORS | The Regents of the University of California (US) | 2022-10-19 | — | — | EP | disclosed |
| US-20220213117-A1 | PRODRUGS OF MODULATORS OF THE NMDA RECEPTOR | H. LUNDBECK A/S (DK) | 2022-07-07 | — | — | US | disclosed |
| WO-2022129041-A1 | PRODRUGS OF 3-BENZOAMIDO-2-AMINOPROPIONIC ACID DERIVATIVES AS MODULATORS OF THE NMDA RECEPTOR | H. LUNDBECK A/S (DK) | 2022-06-23 | — | — | WO | disclosed |
| US-11358971-B2 | Prodrugs of modulators of the NMDA receptor | H. LUNDBECK A/S (DK) | 2022-06-14 | — | — | US | disclosed |
| CN-114008053-A | Prodrugs of NMDA receptor modulators | H.隆德贝克有限公司 | 2022-02-01 | — | — | CN | disclosed |
| CN-107922394-B | 3-tetrazolyl-benzene-1, 2-disulfonamide derivatives as metallo-beta-lactamase inhibitors | 默沙东公司 | 2021-07-13 | — | — | CN | disclosed |
| WO-2021119199-A1 | ALPHA-5 BETA-1 INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-06-17 | — | — | WO | disclosed |
| US-20210171455-A1 | ALPHA-5 BETA-1 INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-06-10 | — | — | US | disclosed |
| EP-3313832-B1 | 3-TETRAZOLYL-BENZENE-1,2-DISULFONAMIDE DERIVATIVES AS METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME (US) | 2021-02-24 | — | — | EP | disclosed |
| US-5648368-A | ANTICOAGULANTS | MERCK & CO., INC. (US) | 1997-07-15 | — | — | US | disclosed |
| EP-0760658-A1 | COMPOUNDS FOR INHIBITING OSTEOCLAST-MEDIATED BONE RESORPTION | MERCK & CO. INC. (US) | 1997-03-12 | — | — | EP | disclosed |
| WO-1996037492-A1 | ISOXAZOLINE AND ISOXAZOLE DERIVATIVES AS INTEGRIN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-11-28 | — | — | WO | disclosed |
| EP-0730590-A1 | NOVEL ISOXAZOLINE AND ISOXAZOLE FIBRINOGEN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-09-11 | — | — | EP | disclosed |
| EP-0673247-A4 | FIBRINOGEN RECEPTOR ANTAGONISTS. | MERCK & CO INC (US) | 1996-05-01 | — | — | EP | disclosed |
| WO-1996010035-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1996-04-04 | — | — | WO | disclosed |
| WO-1995032710-A1 | COMPOUNDS FOR INHIBITING OSTEOCLAST-MEDIATED BONE RESORPTION | MERCK & CO., INC. (US) | 1995-12-07 | — | — | WO | disclosed |
| EP-0673247-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS | MERCK & CO. INC. (US) | 1995-09-27 | — | — | EP | disclosed |
| WO-1995014683-A1 | NOVEL ISOXAZOLINE AND ISOXAZOLE FIBRINOGEN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-06-01 | — | — | WO | disclosed |
| WO-1994012181-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1994-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171455-A1 | ALPHA-5 BETA-1 INHIBITORS | SCN5A, PSMA5, API5 | KYNU 2736/4885ALDH1A1 227/4885ALOX15 537/4885 |
| US-11358971-B2 | Prodrugs of modulators of the NMDA receptor | GRIN3A, GRIN1, GRIN2A | KYNU 53/4885ALDH1A1 2194/4885ALOX15 2137/4885 |
| US-11530180-B2 | Alpha-5 beta-1 inhibitors | SCN5A, PSMA5, API5 | KYNU 2736/4885ALDH1A1 227/4885ALOX15 537/4885 |
| US-20220213117-A1 | PRODRUGS OF MODULATORS OF THE NMDA RECEPTOR | GRIN3A, GRIN1, GRIN2A | KYNU 53/4885ALDH1A1 2194/4885ALOX15 2137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.